John C. Reed

Dr. John C. Reed is President and Chief Executive Officer of the Burnham Institute for Medical Research, one of the nation’s top biomedical research institutes, with more than 800 employees and with operations in San Diego and Santa Barbara, California, and in Orlando, Florida. His research interests have focused primarily on cancer, but he has also made important contributions in the areas of AIDS, autoimmunity, stroke and other diseases. Dr. Reed has been a pioneer in delineating the fundamental mechanisms that regulate programmed cell death, a process by which cells in the body commit suicide through activation of a genetically controlled program. Much of his work has revealed how defects in programmed cell death contribute to diseases such as cancer, resulting in novel strategies for therapeutic intervention. Dr. Reed is author of over 800 peer-reviewed scientific articles and over 50 book chapters. He was recognized by the Institute for Scientific Information as the world's most cited scientist in all areas of scientific inquiry from 1997-1999, and was recognized as one of the top 10 “Doctors of the Decade” for publication citations covering the decade 1995-2005, receiving more citations world wide than any other scientist in the field of “cell biology” and in the field of “general biomedicine.”

Dr. Reed leads several drug discovery efforts at the Burnham, including serving as director of the National Center for Chemical Library Screening based at Burnham and director of the Cancer Drug Discovery Group sponsored by the National Cancer Institute (NCI). His inventions have resulted in over 70 U.S. Patents or Patent applications, and have spawned numerous drug-discovery programs, including novel therapeutics that restore the programmed cell death machinery of cancer cells, currently in Phase II and Phase III clinical testing for patients with treatment-refractory cancers. He is the recipient of numerous awards for his research accomplishments, and has been awarded over 80 research grants by a variety of funding agencies, including the NIH, ACS, Leukemia Society of America, CaP-CURE, ABC2, and the Susan B Komen Breast Cancer Foundation.

Dr. Reed serves or has served on the editorial boards of numerous scientific journals, and as an advisor to the National Institutes of Health (NIH), American Cancer Society (ACS), and the American Association for Cancer Research (AACR). Dr. Reed also serves or has served as an advisor and consultant to numerous biotechnology and pharmaceutical companies, and on the Board of Directors of several public biopharmaceutical companies.